A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma

Phase 2 Completed 18 enrolled Dana-Farber Cancer Institute Brigham and Women's Hospital · collab Massachusetts General Hospital · collab National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to determine how effective and how safe it is to give an Epstein-Barr Virus (EBV) immunotherapy product to participants with nasopharyngeal carcinoma (NPC) associated with EBV that has come back or spread to other parts of the participant's body. This is phase II study with the aim of establishing a baseline of efficacy.

Timeline

Start: 2009-04
Primary completion: 2012-03
Completion: 2017-02

Publications

Results Huang J, Fogg M, Wirth LJ, Daley H, Ritz J, Posner MR, Wang FC, Lorch JH. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer. 2017 Jul 15;123(14):2642-2650. doi: 10.1002/cncr.30541. Epub 2017 Feb 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Epstein-Barr Virus Specific Immunotherapy	Cell therapy	1e+08 unknown	—

A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma

Summary

Timeline

Publications

Drugs

Indications